Guggenheim Reiterates Buy Rating on Abivax, Keeps $175 Price Target
Guggenheim reiterated its Buy rating on Abivax and a $175 price target. The target implies 124.5% upside from the Oct. 19 close of $77.95.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.